Search Results
Your search for ,Non matches 5540 pages
Showing 3601 - 3650Atezolizumab: Another Therapeutic Option for Patients With Previously Treated Non–Small Cell Lung Cancer
The OAK study—recently reported by Rittmeyer and colleagues and reviewed in this issue of The ASCO Post—is the first study to show patients with previously treated non–small cell lung cancer (NSCLC) treated with a humanized antibody (atezolizumab, Tecentriq) directed against the programmed cell...
Atezolizumab Improves Overall Survival vs Docetaxel in Previously Treated Non–Small Cell Lung Cancer
In the phase III OAK trial reported in The Lancet by Achim Rittmeyer, MD, of Lungenfachklinik Immenhausen, Germany, and colleagues, treatment with the anti–programmed cell death ligand 1 (PD-L1) antibody atezolizumab (Tecentriq) improved overall survival vs docetaxel in previously treated non–small ...
Geriatric Oncology: A Multidisciplinary Approach in a Global Environment
Geriatrics for the Oncologist is guest edited by Stuart M. Lichtman, MD, FACP, FASCO, and developed in collaboration with the International Society of Geriatric Oncology (SIOG). Dr. Lichtman is an Attending Physician at Memorial Sloan Kettering Cancer Center, Commack, New York, and Professor of...
Combination Therapy With Pembrolizumab in Metastatic Nonsquamous NSCLC
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On May 10, 2017, pembrolizumab (Keytruda) was granted accelerated...
FDA Broadens Ceritinib Indication
On May 26, 2017, the U.S. Food and Drug Administration (FDA) granted regular approval to ceritinib (Zykadia), a kinase inhibitor for patients with metastatic non–small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. In April...
Selected Novel Agents in Development for Multiple Myeloma
Here are several abstracts selected from the proceedings of the 2016 America Society of Hematology (ASH) Annual Meeting & Exposition, highlighting newer therapeutics for the development for patients with relapsed or refractory multiple myeloma. For full details of these study abstracts, visit...
Proton Therapy Associated With Fewer Sequelae in the Treatment of Head and Neck Cancer
Radiation oncology is vital to the management of patients with cancer of the head and neck, and for certain patients, proton therapy may offer significant benefit over intensity-modulated radiation therapy, according to Walter J. Curran, MD, Executive Director of the Winship Cancer Institute of...
Targeted Therapy in the Age of Immunotherapy in Head and Neck Cancer
The impact of targeted therapies in head and neck cancer has been limited, but we can strategize to integrate the development of targeted and immunotherapeutic agents, according to Christine H. Chung, MD, Senior Member and Chair in the Department of Head and Neck-Endocrine Oncology at Moffitt...
Alice Tsang Shaw, MD, PhD, and Tony Mok, MD, on NSCLC: Results From the ALEX and ARCHER 1050 Trials
Alice Tsang Shaw, MD, PhD, of Massachusetts General Hospital, and Tony Mok, MD, of the Chinese University of Hong Kong, discuss their two ASCO-featured abstracts on non–small cell lung cancer: alectinib vs crizotinib in treatment-naive advanced ALK+ disease, and dacomitinib vs gefitinib for...
ALEX Trial: Alectinib vs Crizotinib in Untreated Advanced ALK-Positive NSCLC
As reported at the recent ASCO Annual Meeting and in The New England Journal of Medicine by Peters et al, the phase III ALEX trial has shown improvement in progression-free survival with alectinib (Alecensa) vs crizotinib (Xalkori) in the first-line treatment of advanced ALK-positive...
Adjuvant Gefitinib Delays Recurrence in EGFR-Positive NSCLC
Adjuvant therapy with gefitinib (Iressa), an epidermal growth factor receptor (EGFR)-targeted agent, was more successful at preventing recurrence than standard-of-care chemotherapy, in a phase III study of patients with EGFR-positive non–small cell lung cancer (NSCLC).1 Gefitinib extended...
Effect of Previous Radiotherapy on Outcome With Pembrolizumab in NSCLC
In a single-site experience reported in The Lancet Oncology by Shaverdian et al, patients with advanced non–small cell lung cancer (NSCLC) in the phase I KEYNOTE-001 trial of pembrolizumab (Keytruda) were found to have better outcomes if they had received prior radiotherapy. Study Details...
ASCO 2017: Research Suggests Possible New Treatment for EGFR-Positive Lung Cancer
Findings from a phase III clinical trial point to a potential new treatment for patients newly diagnosed with advanced, epidermal growth factor receptor (EGFR)-positive non–small cell lung cancer (NSCLC). Compared to the EGFR inhibitor gefitinib (Iressa), one of the standard targeted...
ASCO 2017: ALEX Study: Alectinib Halts Lung Cancer Growth More Than a Year Longer Than Crizotinib
Findings from a phase III clinical trial point to a more effective initial treatment for patients with ALK-positive non–small cell lung cancer (NSCLC). Compared to the current standard of care, crizotinib (Xalkori), the newer ALK inhibitor alectinib (Alecensa) halted cancer growth for a...
Daniel A. Goldstein, MD, on Pembrolizumab for Lung Cancer: Saving Costs by Adjusting Dosage
Daniel A. Goldstein, MD, of Emory University and Rabin Medical Center, discusses his study findings that show nearly $1 billion in savings when patients receive personal weight-based doses instead of a predetermined fixed dose for treatment of PD-L1-positive non–small cell lung cancer. (Abstract...
ASCO 2017: New High-Intensity Genomic Sequencing Approach Detects Circulating Tumor DNA at a High Rate
In a study of 124 patients with advanced breast, lung, and prostate cancers, a new high-intensity genomic sequencing approach detected circulating tumor DNA at a high rate. In 89% of patients, at least one genetic change detected in the tumor was also detected in the blood. Overall, 627 (73%)...
ASCO 2017: Steady Decrease in Severe Health Problems for Childhood Cancer Survivors
Treatments for childhood cancer are often intense and carry the risk of lifelong health problems for survivors. An analysis of 23,600 childhood cancer survivors in the Childhood Cancer Survivor Study (CCSS), funded by the National Institutes of Health, found that the rate of severe health problems...
ATS 2017: Among All Cancers, Lung Cancer Appears to Put Patients at Greatest Suicide Risk
A lung cancer diagnosis appears to put patients at the greatest risk of suicide when compared to the most common types of non-skin cancers, according to new research presented at the 2017 American Thoracic Society International Conference (Abstract 8321). Researchers analyzed 3,640,229 patients in ...
Japanese Phase III Trial of Alectinib vs Crizotinib in ALK-Positive NSCLC
The Japanese phase III J-ALEX trial has shown improved progression-free survival with alectinib (Alecensa) vs crizotinib (Xalkori) in ALK inhibitor–naive patients with ALK-positive non–small-cell lung cancer (NSCLC). Results were reported by Hida et al in The Lancet. Study Details In...
Clinical Implications of Luminal and Basal Subtyping of Prostate Cancer
As reported by Zhao et al in JAMA Oncology, luminal B prostate cancers carry a worse overall prognosis than luminal A and basal-like cancers, but luminal B tumors respond better to postoperative androgen-deprivation therapy. Study Details In the study, the PAM50 classifier was used to subtype...
Pembrolizumab in Advanced PD-L1–Positive Endometrial Cancer
Pembrolizumab (Keytruda) showed activity in previously treated patients with advanced programmed cell death ligand 1 (PD-L1)–positive endometrial cancer in a cohort of the phase Ib KEYNOTE-028 study. These findings were reported in the Journal of Clinical Oncology by Ott et al. Study Details ...
FDA Broadens Ceritinib Indication to Previously Untreated ALK-Positive Metastatic NSCLC
On May 26, 2017, the U.S. Food and Drug Administration (FDA) granted regular approval to ceritinib (Zykadia) for patients with metastatic non–small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. In April 2014,...
Special Awards and Lectures Presented During 2017 ASCO Annual Meeting
Recipients of ASCO’s Notable Awards and Lectures are individuals who have made extraordinary contributions to the research and treatment of patients with cancer. These individuals were honored during several special sessions held during ASCO’s 53rd Annual Meeting, where more than 30,000 physicians, ...
FDA Oncology Drug Approvals Granted Between August 2016 and May 18, 2017
Pembrolizumab (Keytruda), an anti–programmed cell death protein 1 (PD-1) therapy, received regular approval from the U.S. Food and Drug Administration (FDA) for patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing...
Non–V600 BRAF Mutations in Metastatic Colorectal Cancer
As reported by Jones et al in the Journal of Clinical Oncology, BRAF mutations occurring outside of codon 600 are found in a small proportion of cases of metastatic colorectal cancer and are associated with improved clinical outcome. Study Details The retrospective cohort study involved 9,643...
Precision Medicine and My Own Activism Are Keeping Me Alive
In 2009, I was living my dream. My work as a business development manager for a technology company was thriving; I had a satisfying social life; I was active in sports, especially hiking and biking; and I was involved in social justice causes as a volunteer at San Quentin State Prison, helping...
OPTIMIZE-2 Trial Offers Reassuring Data on Deescalation of Bisphosphonate Therapy for Breast Cancer–Related Bone Metastases
Bisphosphonates were first synthesized more than a century ago, with their initial usage restricted to a range of industrial processes until their potential clinical relevance was appreciated in the late 1960s.1 Then, following development for the treatment of osteoporosis and Paget’s disease of...
Osimertinib in Metastatic EGFR T790M–Mutant NSCLC After EGFR Inhibitor Therapy
On March 30, 2017, osimertinib (Tagrisso) was granted regular approval for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M–mutant non–small cell lung cancer (NSCLC), as detected by a U.S. Food and Drug Administration (FDA)-approved test, who have progressed...
Unique Challenges Facing Young Women With Breast Cancer
According to the American Cancer Society, over 252,700 new cases of invasive breast cancer will be diagnosed in 2017, and about 40,610 women will die of their disease. Between 7% and 10% of those new cases will be diagnosed in women younger than age 40, accounting for more than 40% of all cancer...
Niraparib in Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
On March 27, 2017, the oral poly ADP-ribose polymerase (PARP) inhibitor niraparib (Zejula) was approved for maintenance treatment of patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy.1,2...
JNCCN 360, the Source for Tumor-Specific News and Treatment Updates, Available Now
Launched during the National Comprehensive Cancer Network® (NCCN®) 22nd Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care™, JNCCN360.org is the latest resource from the Journal of the National Comprehensive Cancer Network (JNCCN). Currently available for breast...
Effect of Fixed Second Appointments on Breast Cancer Screening Attendance
In a UK study reported in The Lancet Oncology, Allgood et al found that provision of a second timed appointment for breast cancer screening improved screening rates among women who did not attend a first offered appointment. Study Details In the study, women who were invited for breast screening...
Common Causes of Death Predominate Among Long-Term Colorectal Cancer Survivors
Patients with colorectal cancer who survive at least 5 years are increasingly likely to die from causes that are common in the general population, highlighting the importance of screening and lifestyle modification, suggested a large cohort study conducted in California.1 The analysis of more than...
Alice T. Shaw, MD, PhD, Joins LUNGevity Foundation Scientific Advisory Board
LUNGevity Foundation has announced that Alice T. Shaw, MD, PhD, joined its Scientific Advisory Board, a group of 20 world-renowned scientists and researchers who guide LUNGevity’s research program. The Scientific Advisory Board is integral to the Foundation, overseeing the scientific strategy and...
Pharmaceutical Companies Collaborate in NCCN Oncology Research Program
The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) has funded three studies in its first multi-industry collaborative research project, in which Boehringer Ingelheim Pharmaceuticals and Eli Lilly and Company are collaborating with NCCN to study combination...
Atezolizumab Improves Overall Survival in Small Subset of Patients With Triple‑Negative Breast Cancer
Triple-negative breast cancer is an aggressive disease with no approved targeted therapy, and it remains challenging to treat. Early data from a phase I study suggest that the PD-L1 inhibitor atezolizumab (Tecentriq) can extend the lives of a subset of women who respond to this checkpoint...
European Commission Approves Nivolumab for Head and Neck Squamous Cell Carcinoma Progressing After Platinum Therapy
On April 28, 2017, the European Commission approved nivolumab (Opdivo) as monotherapy for the treatment of squamous cell carcinoma of the head and neck (SCCHN) in adults with disease progression on or after platinum-based therapy. Nivolumab is the first and only immuno-oncology treatment that has...
Triple‑Modality Therapy Achieves Good Control in Inflammatory Breast Cancer
Contemporary triple-modality therapy achieves excellent locoregional tumor control of inflammatory breast cancer, with only 4 locoregional recurrences out of 114 patients treated at The University of Texas MD Anderson Cancer Center, Houston. The investigators described their approach at the...
Provision of Genetic Services to Women With Breast Cancer: We Must Do Much Better
Genetic testing for inherited cancer susceptibility is increasingly part of the care of cancer patients and their relatives. Early clinical guidelines recommended BRCA1/2 testing for women diagnosed with breast or ovarian cancer if they also have a significant family cancer history or Ashkenazi...
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): 2017 Guidelines
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): 2017 Guidelines In 1996, the National Comprehensive Cancer Network® (NCCN®) published its first set of Clinical Practice Guidelines in Oncology®, covering 8 tumor types. Guidelines are now published for more than 60 tumor types and...
One in Five Cancers Diagnosed in the United States Is a Rare Cancer
About one in five cancer diagnoses in the United States is a rare cancer, according to new research from the American Cancer Society. The report, published by DeSantis et al in CA: A Cancer Journal for Clinicians, found rare cancers account for more than two in three cancers occurring in children...
RECIL 2017: New Response Evaluation Criteria in Lymphoma Clinical Trials
New criteria for evaluating response in lymphoma clinical trials—RECIL 2017—have been developed by an International Working Group with the aim of harmonizing criteria with the Response Evaluation Criteria in Solid Tumors (RECIST). The new criteria were reported by Younes et al in Annals ...
AUA 2017: Phase III Study of Blue Light Cystoscopy With Optical Imaging Agent in Bladder Cancer
New phase III study results of blue light flexible cystoscopy (BLFC) with an optical imaging agent (Hexvix/Cysview) were presented by Daneshmand et al during a late-breaking plenary session at the 2017 American Urological Association (AUA) Annual Meeting (Abstract PPTLBA-02). Major Findings The...
MEK Inhibitor Selumetinib and Docetaxel in KRAS-Mutant Advanced NSCLC
A phase III trial (SELECT-1) has shown no improvement in progression-free survival with the addition of the MEK inhibitor selumetinib to docetaxel in the second-line treatment of patients with KRAS-mutant non–small cell lung cancer (NSCLC). Trial results were reported by Jänne et al in...
Durvalumab With Olaparib or Cediranib in Women’s Cancers
As reported in the Journal of Clinical Oncology by Lee et al, a phase I study has shown activity of the combination of the programmed cell death ligand 1 (PD-L1) inhibitor durvalumab with either the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib (Lynparza) or vascular endothelial growth...
Brigatinib in Advanced Crizotinib-Refractory ALK-Positive NSCLC
As reported by Kim et al in the Journal of Clinical Oncology, the phase II ALTA trial showed that the next-generation oral ALK inhibitor brigatinib produced a high response rate, including intracranial responses, in patients with advanced crizotinib-refractory non–small cell lung cancer...
ASCO 2017: Gefitinib Treatment Can Delay Recurrence of Intermediate-Stage Lung Cancer
The targeted therapy gefitinib (Iressa) appears more effective in preventing recurrence after lung cancer surgery than the standard of care, chemotherapy. In a phase III clinical trial, patients with epidermal growth factor receptor (EGFR)-positive, stage II to IIIA non–small cell lung cancer ...
New Canadian Guideline Provides Advice to Physicians to Avoid Overprescribing of Opioids
Opioid overdoses are claiming the lives of thousands of Canadians. The impact of the opioid crisis continues to be devastating to individuals, families, and communities. Inappropriate prescribing of opioids has led to long-term dependence on this class of drugs. To help address problematic...
FDA Approves Pembrolizumab as First-Line Combination Therapy With Pemetrexed and Carboplatin for Metastatic Nonsquamous NSCLC
On May 10, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda), an anti–programmed cell death protein 1 (PD-1) therapy, in combination with pemetrexed (Alimta) and carboplatin for the first-line treatment of metastatic nonsquamous non–small cell lung cancer...
Ensuring Equitable Cancer Care for All Patients
Cancer is the second-leading cause of death across the globe. Significant efforts, such as the National Cancer Moonshot Initiative and The University of Texas MD Anderson Cancer Center’s Moon Shots Program, will drive advances in cancer prevention, screening, and treatment. However, right now,...
